ag-1549 has been researched along with amprenavir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, X; Geleziunas, R; Hesselgesser, J; Jin, H; Jones, GS; Kim, CU; Tsiang, M; Wright, M; Yu, F; Zeynalzadegan, A | 1 |
2 other study(ies) available for ag-1549 and amprenavir
| Article | Year |
|---|---|
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
Topics: Anti-HIV Agents; Catalytic Domain; CD4-Positive T-Lymphocytes; Cell Line; Cells, Cultured; Drug Evaluation, Preclinical; Drug Resistance, Viral; Drug Synergism; HIV Integrase; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Molecular Structure; Mutation; Protein Structure, Tertiary; Recombinant Proteins; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; T-Lymphocytes | 2009 |
New drugs in development.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Imidazoles; Kidney Diseases; Lopinavir; Oxazines; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 1998 |